title: Cellular and molecular pharmacology of oxaliplatin.
abstract: Oxaliplatin, a diaminocyclohexane-containing platinum, has a spectrum of activity and mechanisms of action and resistance that appear to be different from those of other platinum-containing compounds, notably cisplatin. The first part of this review describes the differences between oxaliplatin and cisplatin in terms of their spectrum of activity and adduct formation and then goes on to discuss molecular and cellular experimental data that potentially explain them. Particular emphasis is placed on the differential role of DNA repair mechanisms. In addition, the anticancer effects of oxaliplatin are optimized when it is administered in combination with other anticancer agents, such as 5-fluorouracil, gemcitabine, cisplatin, or carboplatin; topoisomerase I inhibitors; and taxanes. In vitro and preclinical combination data that could optimize oxaliplatin-based chemotherapy are also reviewed.
authors.affiliation: Department of Medicine, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. raymond@igr.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Raymond
authors.forename: Sandrine
authors.initials: S
authors.lastname: Faivre
authors.forename: Stephen
authors.initials: S
authors.lastname: Chaney
authors.forename: Jan
authors.initials: J
authors.lastname: Woynarowski
authors.forename: Esteban
authors.initials: E
authors.lastname: Cvitkovic
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001711:Biotransformation; D018736:DNA Adducts; D004260:DNA Repair; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin
chemical_list: D000970:Antineoplastic Agents; D018736:DNA Adducts; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin